Literature DB >> 23830842

Stability of creatinine and cystatin C in whole blood.

E M Spithoven1, S J L Bakker, J E Kootstra-Ros, P E de Jong, R T Gansevoort.   

Abstract

BACKGROUND: As yet little is known about the effect of delayed separation of whole blood stored at room temperature on the stability of the kidney function markers creatinine and cystatin C.
METHODS: We used plasma samples of 45 patients with a wide range of creatinine and cystatin C concentration. Samples were sent by post as whole blood, and differences in creatinine and cystatin C concentrations when measured (by enzymatic assay and PETIA, respectively) in plasma separated shortly after blood withdrawal or in plasma obtained after delayed separation at 24, 48 and 72 h. Intra- and inter-assay variability was assessed and total change limit was calculated to assess analyte stability.
RESULTS: Total change limit was 3.3% for creatinine and 3.9% for cystatin C. In whole blood creatinine and cystatin C remained stable up to 48 h. Delayed separation of whole blood did not induce more variability in measured concentrations of both analytes. Glomerular filtration rate estimated with the CKD-EPI equations showed less than 3 mL/min/1.73 m² difference when using creatinine or cystatin C concentration measured in plasma separated up to 48 h after blood withdrawal compared to plasma separated shortly after blood withdrawal. The new CKD-EPI equation that uses creatinine as well as cystatin C to estimate GFR showed even at 72 h less than 3 mL/min/1.73 m² difference.
CONCLUSIONS: Creatinine and cystatin C remain stable in whole blood stored at room temperature up to 48 h before separation, and changes in these analytes during this time period do not affect variability and eGFR.
© 2013.

Entities:  

Keywords:  Creatinine; Cystatin C; Enzymatic assay; Stability; Whole blood

Mesh:

Substances:

Year:  2013        PMID: 23830842     DOI: 10.1016/j.clinbiochem.2013.06.022

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Joost P H Drenth; Hedwig d'Agnolo; Niek F Casteleijn; Johan W de Fijter; Tom J Gevers; Peter Kappert; Dorien J M Peters; Mahdi Salih; Darius Soonawala; Edwin M Spithoven; Vicente E Torres; Folkert W Visser; Jack F M Wetzels; Robert Zietse; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2013-12-15       Impact factor: 8.860

2.  β2-microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease.

Authors:  Michel M Joosten; Jennifer K Pai; Monica L Bertoia; Ron T Gansevoort; Stephan J L Bakker; John P Cooke; Eric B Rimm; Kenneth J Mukamal
Journal:  J Am Heart Assoc       Date:  2014-06-30       Impact factor: 5.501

3.  Effect of temperature and time delay in centrifugation on stability of select biomarkers of nutrition and non-communicable diseases in blood samples.

Authors:  Ransi Ann Abraham; Praween K Agrawal; Rajib Acharya; Avina Sarna; Sowmya Ramesh; Robert Johnston; Arjan de Wagt; Nizamuddin Khan; Akash Porwal; Sucheta Banerjee Kurundkar; Arvind Pandey; Raghu Pullakhandam; Krishnapillai Madhavan Nair; Geeta Trilok Kumar; H P S Sachdev; Umesh Kapil; Renu Saxena; Sila Deb; Ajay Khera; Lakshmy Ramakrishnan
Journal:  Biochem Med (Zagreb)       Date:  2019-06-15       Impact factor: 2.313

4.  Evaluation of the accuracy of an electronic point-of-care analyzer to quantify blood creatinine concentration in goats.

Authors:  Melanie J Boileau; Leslie Wagner; Jared D Taylor
Journal:  J Vet Intern Med       Date:  2021-02-24       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.